MX341117B - Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab. - Google Patents

Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab.

Info

Publication number
MX341117B
MX341117B MX2012002907A MX2012002907A MX341117B MX 341117 B MX341117 B MX 341117B MX 2012002907 A MX2012002907 A MX 2012002907A MX 2012002907 A MX2012002907 A MX 2012002907A MX 341117 B MX341117 B MX 341117B
Authority
MX
Mexico
Prior art keywords
treatment
autoimmune
epratuzumab
inflammatory diseases
relates
Prior art date
Application number
MX2012002907A
Other languages
English (en)
Other versions
MX2012002907A (es
Inventor
Novotney-Barry Anna-Marie
Hulhoven Réginald
L Parker Gerald
A Hoskin Violet
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of MX2012002907A publication Critical patent/MX2012002907A/es
Publication of MX341117B publication Critical patent/MX341117B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un Epratuzumab para usarse en el tratamiento del lupus eritematoso sistémico (SLE), en donde epratuzumab está adaptado para ser administrable intravenosamente en una dosis particular fija de 600 mg una vez cada semana durante 4 veces a una dosis acumulada de 2400 mg de epratuzumab en un ciclo de tratamiento de 12 semanas, y en donde epratuzumab está adaptado para ser administrable en más de un ciclo de tratamiento de 12 semanas.
MX2012002907A 2009-09-18 2010-08-26 Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab. MX341117B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24379709P 2009-09-18 2009-09-18
PCT/EP2010/005225 WO2011032633A1 (en) 2009-09-18 2010-08-26 Treatment of autoimmune and inflammatory diseases with epratuzumab

Publications (2)

Publication Number Publication Date
MX2012002907A MX2012002907A (es) 2012-04-30
MX341117B true MX341117B (es) 2016-08-09

Family

ID=43063209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002907A MX341117B (es) 2009-09-18 2010-08-26 Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab.

Country Status (13)

Country Link
US (1) US20110070227A1 (es)
EP (1) EP2478012B1 (es)
JP (1) JP5816905B2 (es)
KR (1) KR20120100914A (es)
CN (1) CN102574920A (es)
AU (1) AU2010294905B2 (es)
BR (1) BR112012006035A2 (es)
CA (1) CA2774244A1 (es)
EA (1) EA026902B1 (es)
ES (1) ES2608661T3 (es)
IN (1) IN2012DN02196A (es)
MX (1) MX341117B (es)
WO (1) WO2011032633A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG162788A1 (en) 2005-06-14 2010-07-29 Amgen Inc Self-buffering protein formulations
EP2294178B1 (en) 2008-05-23 2014-07-16 Siwa Corporation Methods for facilitating regeneration
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
NZ707490A (en) * 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
IL251210B2 (en) * 2014-09-19 2023-12-01 Siwa Corp Anti-aging antibodies for the treatment of inflammation and autoimmune disorders
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP4067386A1 (en) 2016-02-19 2022-10-05 Siwa Corporation Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CA3057829A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
DK3612537T3 (da) 2017-04-18 2022-08-08 Medimmune Ltd Pyrrolobenzodiazepinkonjugater
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
WO2000074718A1 (en) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
PT3284753T (pt) * 2002-10-17 2020-05-04 Genmab As Anticorpos monoclonais humanos contra cd20 para utilização no tratamento da esclerose múltipla
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ZA200809776B (en) * 2006-05-30 2010-03-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof

Also Published As

Publication number Publication date
EA201270433A1 (ru) 2012-10-30
AU2010294905A1 (en) 2012-04-05
WO2011032633A1 (en) 2011-03-24
JP2013505205A (ja) 2013-02-14
EP2478012A1 (en) 2012-07-25
JP5816905B2 (ja) 2015-11-18
EP2478012B1 (en) 2016-11-09
EA026902B1 (ru) 2017-05-31
US20110070227A1 (en) 2011-03-24
MX2012002907A (es) 2012-04-30
ES2608661T3 (es) 2017-04-12
IN2012DN02196A (es) 2015-08-21
CN102574920A (zh) 2012-07-11
CA2774244A1 (en) 2011-03-24
BR112012006035A2 (pt) 2019-09-24
AU2010294905B2 (en) 2016-09-22
KR20120100914A (ko) 2012-09-12

Similar Documents

Publication Publication Date Title
MX2012002907A (es) Tratamiento de enfermedades autoinmunes e inflamatorias con epratuzumab.
MX2011011925A (es) Anticuerpos triespecificos o tetraespecificos.
CA145237S (en) Combined cover and saucer
CA141065S (en) Dual c clip
CA144920S (en) Bottle
CA144362S (en) Combined dishwashing and scrubbing tool
AU333674S (en) Bottle
CA140016S (en) Battery
WO2012106407A3 (en) Diagnostic and therapeutic methods and products related to anxiety disorders
WO2011083150A3 (en) Obesity small molecules
MY159398A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
WO2014078866A3 (en) Engineered immunoglobulins with extended in vivo half-life
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
CA144229S (en) Drinking flask
CA147873S (en) Teapot
MX2014001850A (es) Anticuerpos que enlazan alfa-v beta-8 integrina.
CA138917S (en) Beverage package
MY161868A (en) Anti-bv8 antibodies and uses thereof
CA141066S (en) Dual c clip
CA144264S (en) Toy construction cell component
CA143665S (en) Boot
CA143664S (en) Boot
AU327974S (en) Bottle
AU327953S (en) Bottle
AU327990S (en) Bottle

Legal Events

Date Code Title Description
FG Grant or registration